Ambagon Therapeutics Launches With $85 Million Series A to Advance Pioneering Molecular Glue Platfor

Modular platform enables development of molecular glue stabilizers addressing intrinsically disordered proteins, a largely undrugged target classInitial discovery pipeline focused on high-value targets in oncologySAN FRANCISCO--(BUSINESS WIRE)--Ambagon Therapeutics, a biotechnology company unlocking intrinsically di...

Related Keywords

California ,United States ,Netherlands ,San Carlos ,Matt Crenson ,Nancy Pryer ,Scott Clarke ,Melissa Mccracken ,Michelle Arkin ,Adam Rosenberg ,Christian Ottmann ,Luc Brunsveld ,Director Of The Small Molecule Discovery Center ,Eindhoven University Of Technology ,Mission Biocapital ,Ventures Fund ,Ambagon Therapeutics ,Droia Ventures ,Inkef Capital ,Abbvie Ventures ,Surveyor Capital ,Pharmaceutical Chemistry ,Small Molecule Discovery Center ,Chemical Biology ,Eindhoven University ,Associate Professor ,Molecular Cell ,Structural Biology ,Chief Executive Officer Scott Clarke ,Tizona Therapeutics ,Trishula Therapeutics ,Chief Scientific Officer Nancy Pryer ,Day One Biopharmaceuticals ,Chief Development Officer ,Modular Ambagon Drug Discovery Platform ,